Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 19,055 shares, a growth of 69.4% from the February 12th total of 11,249 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily trading volume, of 9,298 shares, the short-interest ratio is currently 2.0 days. Based on an average daily trading volume, of 9,298 shares, the short-interest ratio is currently 2.0 days. Currently, 0.4% of the company’s stock are short sold.

Institutional Investors Weigh In On Alterity Therapeutics

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of Alterity Therapeutics during the third quarter worth $83,000. HB Wealth Management LLC purchased a new position in Alterity Therapeutics in the 3rd quarter valued at $220,000. Greenleaf Trust increased its stake in Alterity Therapeutics by 88.2% in the 3rd quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after buying an additional 15,000 shares during the period. Finally, Twin Lakes Capital Management LLC increased its stake in Alterity Therapeutics by 2,250.3% in the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after buying an additional 133,333 shares during the period. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Trading Up 1.4%

Shares of ATHE opened at $3.60 on Friday. Alterity Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $7.00. The firm has a 50-day simple moving average of $3.40 and a 200-day simple moving average of $3.80.

Alterity Therapeutics (NASDAQ:ATHE) last issued its quarterly earnings results on Friday, January 30th. The company reported ($0.18) earnings per share (EPS) for the quarter. Equities research analysts predict that Alterity Therapeutics will post -0.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Zacks Research upgraded Alterity Therapeutics to a “hold” rating in a report on Thursday, February 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group began coverage on Alterity Therapeutics in a report on Wednesday, December 17th. They issued a “speculative buy” rating for the company. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.